Source comparison
Comparison: Peptide Stacking Strategies
Tesamorelin + Ipamorelin + Hexarelin High. All three target GH secretion pathways Moderate. Competing for GHSR1a receptors and hepatic clearance Misguided attempt to 'amplify' GH release Redundant. Receptor saturation limits benefit beyond the base blend Tesam
This comparison does not assign a generated winner or score.
- Tesamorelin + Ipamorelin + Hexarelin
- High. All three target GH secretion pathways
- Moderate. Competing for GHSR1a receptors and hepatic clearance
- Misguided attempt to 'amplify' GH release
- Redundant. Receptor saturation limits benefit beyond the base blend
- Tesamorelin + Ipamorelin + BPC-157
- None. GH secretion vs tissue repair signalling
- Minimal. Half-lives and clearance pathways non-overlapping
- Recovery-focused protocols, injury repair research
- Effective. Complementary mechanisms with no receptor competition
- Tesamorelin + Ipamorelin + AOD-9604
- Low. GH vs targeted lipolytic fragment
- Minimal. AOD doesn't compete for GHRH/GHSR1a sites
- Body composition and fat loss research
- Synergistic. GH anabolism paired with direct adipocyte signalling
- Tesamorelin + Ipamorelin + Tesofensine
- None. GH secretion vs CNS appetite/NEAT modulation
- None. Completely separate pharmacokinetic profiles
- Appetite suppression and metabolic rate research
- Highly effective. Addresses two independent variables in body composition
- Tesamorelin + Ipamorelin + Dihexa
- None. GH secretion vs BDNF upregulation
- None. Distinct clearance pathways, non-overlapping half-lives
- Cognitive function and neuroprotection research
- Effective for multi-system protocols; monitor systemic load